Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

NCT03520985 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Stopped Feasibility (low patient accrual and financial reasons)

Conditions

Refractory Multiple Myeloma

Interventions

DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Swiss Cancer Institute